INTRODUCTION AND HYPOTHESIS: Women undergoing InterStim implantation for overactive bladder (OAB) or painful bladder syndrome (PBS) were prospectively evaluated to determine if neuromodulation has any effect on female sexual function (FSF). METHODS: Sexually active women in our InterStim database completed a female sexual function index (FSFI) preoperatively and at 6 months. RESULTS: Of 105 women, 54 have 6-month follow-up data. Of these, 27 were sexually active preoperatively and at follow-up. The mean (standard deviation (SD)) FSFI improved from 18.7 (6.8) preoperatively to 21.0 (6.0) postoperatively; however, this was not statistically significant (p = 0.220). Subgroup analysis of patients with OAB revealed that mean (SD) FSFI preoperatively was 18.6 (8.0) and 22.4 (6.4) at 6 months (p = 0.257). In the PBS group, mean (SD) FSFI was 18.8 (6.3) preoperatively and 18.7 (5.8) at 6 months (p = 0.98). CONCLUSIONS: Neuromodulation does not significantly improve FSF in a heterogenous population. Additional studies are needed to confirm the findings in our study.
INTRODUCTION AND HYPOTHESIS: Women undergoing InterStim implantation for overactive bladder (OAB) or painful bladder syndrome (PBS) were prospectively evaluated to determine if neuromodulation has any effect on female sexual function (FSF). METHODS: Sexually active women in our InterStim database completed a female sexual function index (FSFI) preoperatively and at 6 months. RESULTS: Of 105 women, 54 have 6-month follow-up data. Of these, 27 were sexually active preoperatively and at follow-up. The mean (standard deviation (SD)) FSFI improved from 18.7 (6.8) preoperatively to 21.0 (6.0) postoperatively; however, this was not statistically significant (p = 0.220). Subgroup analysis of patients with OAB revealed that mean (SD) FSFI preoperatively was 18.6 (8.0) and 22.4 (6.4) at 6 months (p = 0.257). In the PBS group, mean (SD) FSFI was 18.8 (6.3) preoperatively and 18.7 (5.8) at 6 months (p = 0.98). CONCLUSIONS: Neuromodulation does not significantly improve FSF in a heterogenous population. Additional studies are needed to confirm the findings in our study.
Authors: Ilker Sen; Metin Onaran; Mustafa Ozgur Tan; Cenk Acar; Ahmet Camtosun; Sinan Sozen; Ibrahim Bozkirli Journal: Urol Int Date: 2007 Impact factor: 2.089
Authors: Rachel N Pauls; Serge P Marinkovic; W Andre Silva; Christopher M Rooney; Steven D Kleeman; Mickey M Karram Journal: Int Urogynecol J Pelvic Floor Dysfunct Date: 2006-07-26